Key facts
- This page summarizes Jaime A. Frias's Form 4 filing for TREACE MEDICAL CONCEPTS, INC. (TMCI).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Mar 2022, 19:21.
Jaime A. Frias - 08 Mar 2022 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)
- Reporting relationship
- Chief Legal Officer
- Issuer ticker
- TMCI
- Reported as of
- 08 Mar 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Lisa Taylor as Attorney-in-fact for Jaime Frias
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Jaime A. Frias filed Form 4 for TREACE MEDICAL CONCEPTS, INC. (TMCI) on 10 Mar 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TMCI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +7,875
- Change %
- +18%
- Price
- $0.000000
- Shares after
- 50,659
- Date
- 08 Mar 2022
- Ownership
- Direct
- Footnotes
- F1, F2, F3
TMCI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 225,549
- Date
- 08 Mar 2022
- Ownership
- Pacific Premiere Trust FBO Jaime A. Frias, IRA
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TMCI
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +60,800
- Change %
- Price
- $0.000000
- Shares after
- 60,800
- Date
- 08 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,800
- Exercise price
- $19.15
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026? subject to Reporting Person's providing continued service to Issuer through each vesting date.
Footnote F2
Includes 7,875 RSUs.
Footnote F3
On April 29, 2021, a Form 4 was filed, which inadvertently reported that, following a stock split related to the Issuer's IPO, the Reporting Person directly owned 42,786 shares of Common Stock. Applying the correct stock split ratio, which rounded down fractional shares, the Reporting Person indirectly owned 42,784 shares. This correction has been reflected in this filing.
Footnote F4
On April 29, 2021, a Form 4 was filed which inadvertently reported that, following a stock split related to the Issuer's IPO, the Reporting Person indirectly owned 225,551 shares of Common Stock. Applying the correct stock split ratio, which rounded down fractional shares, the Reporting Person indirectly owned 225,549 shares. This correction has been reflected in this filing.
Footnote F5
The stock option will vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026; subject to Reporting Person's providing continued service to Issuer through each vesting date.